Bile Acids
Targeted Bile Acid Profiling by UPLC-MS/MS
| Specification | MetwareBio Bile Acid Assay |
|---|---|
| Analytical platform | UPLC-MS/MS |
| Mass spectrometer | SCIEX QTRAP 6500+ |
| Acquisition mode | Multiple reaction monitoring (MRM) |
| Target analytes | 82 bile acids |
| Quantification method | Absolute quantification |
| Calibration | 82 analyte-specific calibration curves with internal-standard correction (r > 0.99) |
Why Choose MetwareBio for Bile Acid Analysis?
Broad Bile Acid Coverage
Absolute Bile Acid Quantification
Selective UPLC-MS/MS Detection
Rigorous Quality Control
Multi-Omics Integration
Bile Acid Assay Coverage
MetwareBio's Bile Acid Targeted Metabolomics panel includes 82 compounds that collectively represent major bile acid pools and transformation routes. The expanded panel includes unconjugated bile acids, glycine- and taurine-conjugated species, bile acids common in human and animal models, and selected oxidized, glucuronidated, sulfated, and other bile acid derivatives. Measuring these compounds within one targeted workflow supports comparison of bile acid synthesis, conjugation, microbial conversion, and downstream metabolite patterns across biological conditions.
| Coverage Group | Representative Targets | Research Value |
| Free / unconjugated bile acids | CA, CDCA, DCA, LCA, UDCA, HDCA, muricholic acids and related species | Core primary/secondary pools and microbial transformation products |
| Glycine-conjugated bile acids | GCA, GCDCA, GDCA, GUDCA, GLCA, GHCA and related derivatives | Conjugation status, enterohepatic circulation, and host bile acid metabolism |
| Taurine-conjugated bile acids | TCA, TCDCA, TDCA, TUDCA, TLCA, THCA, Tα-MCA, Tβ-MCA, Tω-MCA | Conjugation patterns across species and experimental models |
| Oxidized, glucuronidated, and sulfated derivatives | 3-oxo-DCA, 3-oxoCDCA, 7-KLCA, CA-3G, CDCA-24G, LCA-3S, UDCA-3S, CDCA-3,7S and related derivatives | Oxidative transformations, phase II conjugation, and extended bile acid chemistry |
Targeted Bile Acid Quantification Workflow
Quantification
Step-by-Step Workflow of MetwareBio’s Bile Acid Targeted Metabolomics
Bile Acid Data Analysis and Deliverables
Bile Acid Profiling Experience
Applications of Targeted Bile Acid Profiling
Gut Microbiome and Host–Microbiome Interactions
Targeted bile acid profiling provides a functional readout of microbial bile acid metabolism by quantifying primary, secondary, and conjugated bile acid species. Changes in deconjugation, dehydroxylation, and other microbial transformations can be evaluated alongside 16S rRNA sequencing or metagenomics to link microbial composition with bile acid metabolism. This approach is particularly valuable for studying host–microbiome interactions, microbial dysbiosis, and bile acid-mediated communication between the gut microbiota and host.
Liver and Hepatobiliary Disease
Bile acid quantification supports mechanistic studies of liver and hepatobiliary disorders by resolving changes in individual bile acids and conjugation patterns associated with bile acid synthesis, secretion, and enterohepatic circulation. Targeted bile acid analysis can be applied to cholestasis, chronic liver injury, metabolic liver disease, and related experimental models, providing a more detailed biochemical profile than total bile acid measurements and helping characterize disease-associated disturbances in hepatic bile acid metabolism.
Metabolic Disease and Cardiometabolic Regulation
Bile acids act as metabolic signaling molecules through pathways involving receptors such as FXR and TGR5/GPBAR1, linking bile acid metabolism with glucose, lipid, cholesterol, and energy homeostasis. Quantitative bile acid profiling can characterize bile acid alterations associated with obesity, insulin resistance, dyslipidemia, metabolic syndrome, and related interventions. Measuring individual bile acid species helps researchers connect shifts in bile acid composition with metabolic phenotypes and regulatory pathways involved in systemic metabolic dysfunction.
Gastrointestinal and Inflammatory Disease
Altered bile acid composition can influence intestinal physiology, epithelial barrier function, immune responses, and the luminal environment. Targeted bile acid metabolomics enables quantitative comparison of unconjugated, conjugated, and microbially modified bile acids in gastrointestinal studies, helping characterize changes associated with intestinal inflammation, altered transit, malabsorption, and other gastrointestinal conditions. These profiles can also be integrated with microbiome or host molecular data to investigate relationships between bile acid dysregulation and intestinal disease mechanisms.
Published Bile Acid Metabolomics Case Study
Targeted Bile Acid Profiling Reveals Gut–Liver Axis Mechanisms in Chronic Liver Injury
In the 2024 Gut Microbes study, “Multi-omics reveals deoxycholic acid modulates bile acid metabolism via the gut microbiota to antagonize carbon tetrachloride-induced chronic liver injury”, researchers investigated how deoxycholic acid (DCA), gut microbiota, and bile acid metabolism interact in chronic liver injury. Using clinical samples and CCl₄-induced mouse models, the researchers combined DCA intervention, microbiota depletion, 16S rRNA sequencing, metabolomics, and liver transcriptomics to determine whether DCA-mediated protection depends on gut microbial regulation of host metabolism. MetwareBio provided targeted bile acid profiling using LC-MS/MS with MRM-based quantification. The resulting data revealed coordinated changes in DCA and related secondary bile acids and, when integrated with microbiome and transcriptomic results, linked DCA-driven enrichment of Akkermansia muciniphila with altered bile acid metabolism and reduced inflammatory signaling. This analysis provided key metabolic evidence connecting gut microbiota, bile acid remodeling, and chronic liver injury through the gut–liver axis.
Explore More MetwareBio Publications →
Sample Requirements for Bile Acid Analysis
The table below summarizes common sample types and recommended input requirements for bile acid targeted metabolomics. For complete sample preparation and submission requirements, please refer to our Sample Requirements. For uncommon matrices, limited-volume samples, or multi-omics studies using the same specimen, contact MetwareBio to confirm feasibility before sample submission.
| Sample Type | Recommended Input | Minimum Input | Typical Use |
| Plasma / Serum | 100 µL | 20 µL | Circulating bile acid profiling |
| Bile | 100 µL | 20 µL | Direct hepatobiliary bile acid pool |
| Animal Tissue | 100 mg | 20 mg | Tissue-associated bile acid metabolism |
| Feces / Intestinal Contents | 200 mg | 20 mg | Gut-associated and microbially modified bile acid pool |
- Biological replicates: for the supplied bile acid sample guidance, >30 samples per group are recommended for human studies and 8–10 per group for animal studies. Final sample size should also reflect the study design, expected biological variability, and statistical analysis plan.
- Storage and shipping: keep collection and pre-analytical handling consistent across groups. Freeze samples promptly, store at −80 °C, avoid repeated freeze–thaw cycles, and ship frozen samples on sufficient dry ice. Serum/plasma should be separated and aliquoted before freezing whenever possible.
Frequently Asked Questions About Bile Acid Analysis
1. Which bile acids are included in MetwareBio’s targeted bile acid panel?
MetwareBio’s bile acid targeted metabolomics panel provides absolute quantification of 82 predefined bile acids by targeted UPLC-MS/MS. The expanded panel covers major primary and secondary bile acids, unconjugated and glycine- or taurine-conjugated species, muricholic and hyocholic bile acids, and selected oxidized, glucuronidated, and sulfated derivatives. Because bile acid classification can vary among species, primary and secondary bile acids should be interpreted in the appropriate biological context.
2. Does the assay provide absolute bile acid quantification?
Yes. Individual bile acids are reported as concentration-based quantitative results rather than relative signal intensities. The assay uses analyte-specific calibration curves together with isotope-labeled internal-standard correction; the current panel includes 82 calibration curves with correlation coefficients (r) > 0.99 and 15 isotope-labeled internal standards.
3. When should I choose targeted bile acid metabolomics instead of untargeted metabolomics?
Targeted bile acid metabolomics is the preferred approach when the research objective is accurate and reproducible quantification of known bile acids. Untargeted metabolomics is better suited to broad metabolite discovery across many chemical classes, whereas targeted bile acid analysis focuses analytical sensitivity and quantitative performance on a predefined bile acid panel.
4. Will all 82 bile acids be detected in every sample?
No. The 82-analyte panel defines the bile acids the assay is designed to measure, but not every compound will necessarily be detectable or quantifiable in every sample. Actual detection depends on species, sample matrix, physiological or disease state, treatment, and endogenous bile acid abundance.
5. How is targeted bile acid profiling different from a clinical total bile acid test?
Targeted bile acid profiling quantifies individual bile acid species and provides information on bile acid composition and conjugation patterns. A clinical total bile acid test generally reports an aggregate bile acid measurement for clinical assessment. Results from this research assay should therefore not be considered equivalent to a separately validated clinical diagnostic test.
6. What sample types can be used for targeted bile acid analysis?
Common sample types include plasma, serum, bile, animal tissues, feces, and intestinal contents. Sample input requirements vary by matrix, and unusual matrices or limited-volume samples should be evaluated before submission to confirm analytical feasibility.
7. How should samples be stored and shipped for bile acid analysis?
Samples should be collected and handled consistently across experimental groups, frozen promptly, stored at −80 °C, and protected from repeated freeze–thaw cycles. Frozen samples should be shipped on sufficient dry ice. Plasma and serum should preferably be separated and aliquoted before freezing to minimize pre-analytical variation.
8. What results and data analysis are provided for a bile acid targeted metabolomics project?
Typical deliverables include a sample-by-analyte absolute concentration matrix, calibration and quality-control results, statistical analysis, visualization figures, and a final report. Data analysis may include PCA, hierarchical clustering and heatmaps, OPLS-DA with model validation, fold-change and VIP-based differential bile acid screening, and correlation analysis. KEGG pathway analysis, HMDB disease association, and network analysis can be applied when supported by the study design and available differential bile acids.
9. Can bile acid data be integrated with microbiome or other omics datasets?
Yes. Quantitative bile acid profiles can be integrated with 16S rRNA sequencing, metagenomics, transcriptomics, proteomics, or broader metabolomics data. Such multi-omics analysis can help relate changes in bile acid composition and microbial transformation to microbial taxa or functions, host molecular pathways, and biological phenotypes.
Reference
Zhang, L., Zheng, Z., Huang, H., Fu, Y., Chen, T., Liu, C., Yi, Q., Lin, C., Zeng, Y., Ou, Q., & Zeng, Y. (2024). Multi-omics reveals deoxycholic acid modulates bile acid metabolism via the gut microbiota to antagonize carbon tetrachloride-induced chronic liver injury. Gut Microbes, 16(1), 2323236. https://doi.org/10.1080/19490976.2024.2323236
